|
|
Post by orlon on Nov 4, 2015 14:55:41 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, some of its retail investors sabotaging the company by lending their shares to shorts, a partner that apparently is doing little other than set up trials with other drugs and has a secret plan that know else knows about, poor sales data, and a management team that appears to be acting not in the best interest of the stockholders, or their own product for that matter..regardless of what Matt said during the last CC.
I looked back and saw that I bought a thousand shares almost ten years ago for just over $2.50/shr...not a lot of progress. My guess is the company gets delisted and put on the pinks by the end of the first quarter of. 2016...just my opinion based on past history.
|
|
|
|
Post by liane on Nov 4, 2015 15:02:13 GMT -5
Ten years ago, the lowest MNKD traded for was $8.42.
|
|
|
|
Post by joeypotsandpans on Nov 4, 2015 15:02:30 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, some of its retail investors sabotaging the company by lending their shares to shorts, a partner that apparently is doing little other than set up trials with other drugs and has a secret plan that know else knows about, poor sales data, and a management team that appears to be acting not in the best interest of the stockholders, or their own product for that matter..regardless of what Matt said during the last CC. I looked back and saw that I bought a thousand shares almost ten years ago for just over $2.50/shr...not a lot of progress. My guess is the company gets delisted and put on the pinks by the end of the first quarter of. 2016...just my opinion based on past history. Unfortunately your "opinion" carries slightly lower credence than Adnan as my bid continues to sit from the opening bell....but thanks for chiming in lol  |
|
|
|
Post by james on Nov 4, 2015 15:22:27 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, some of its retail investors sabotaging the company by lending their shares to shorts, a partner that apparently is doing little other than set up trials with other drugs and has a secret plan that know else knows about, poor sales data, and a management team that appears to be acting not in the best interest of the stockholders, or their own product for that matter..regardless of what Matt said during the last CC. I looked back and saw that I bought a thousand shares almost ten years ago for just over $2.50/shr...not a lot of progress. My guess is the company gets delisted and put on the pinks by the end of the first quarter of. 2016...just my opinion based on past history. You know effectively zero about finance then. Go to school or stop investing because you are going to lose everything. As liane points out, MNKD did not trade below $8 until the end of 2007. So, I find your statement to be a complete fallacy. |
|
|
|
Post by savzak on Nov 4, 2015 15:24:04 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, ... I'd say just about exactly the same as it was 5 minutes before RBC announced its change of perception. |
|
|
|
Post by patryn on Nov 4, 2015 15:56:25 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, some of its retail investors sabotaging the company by lending their shares to shorts, a partner that apparently is doing little other than set up trials with other drugs and has a secret plan that know else knows about, poor sales data, and a management team that appears to be acting not in the best interest of the stockholders, or their own product for that matter..regardless of what Matt said during the last CC. I looked back and saw that I bought a thousand shares almost ten years ago for just over $2.50/shr...not a lot of progress. My guess is the company gets delisted and put on the pinks by the end of the first quarter of. 2016...just my opinion based on past history. I am curious how many times in the past MNKD has been delisted that you can infer a future for it based on induction? As for the timing of it, I would make my own guess based on the fact that a company has to be out of compliance with listing requirements for NASDAQ for 30 days and then has 90 days to remedy the situation, and then an lengthy appeals process before being delisted that there is a 0% chance that your guess is correct. As for your other claims - in the short term, none of those things you listed would change the financial outlook of MNKD in the next 90 days. In the long term, I don't know of a single company that has survived as a publicly traded company longer than 44 years on the NASDAQ (February of 1971 was when the NASDAQ was founded), so I would say the probability of long term survival of MNKD is 0% Of course, no one I know gets out of life alive either, but maybe someone will prove me wrong. |
|
|
|
Post by orlon on Nov 4, 2015 15:57:38 GMT -5
Seven years ago it was $2.57.
|
|
|
|
Post by liane on Nov 4, 2015 16:03:45 GMT -5
I guess 7 years is "almost 10 years"  |
|
|
|
Post by orlon on Nov 4, 2015 16:07:15 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, some of its retail investors sabotaging the company by lending their shares to shorts, a partner that apparently is doing little other than set up trials with other drugs and has a secret plan that know else knows about, poor sales data, and a management team that appears to be acting not in the best interest of the stockholders, or their own product for that matter..regardless of what Matt said during the last CC. I looked back and saw that I bought a thousand shares almost ten years ago for just over $2.50/shr...not a lot of progress. My guess is the company gets delisted and put on the pinks by the end of the first quarter of. 2016...just my opinion based on past history. Unfortunately your "opinion" carries slightly lower credence than Adnan as my bid continues to sit from the opening bell....but thanks for chiming in lol Hey, it was just an opinion...and seems to have generated a little discussion. BTW: Who is Adnan? |
|
|
|
Post by orlon on Nov 4, 2015 16:08:55 GMT -5
I guess 7 years is "almost 10 years" It's within the margin of error of 5 years plus or minus. |
|
|
|
Post by liane on Nov 4, 2015 16:09:04 GMT -5
Adnan Butt - the author of the latest RBC downgrade.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 4, 2015 16:10:31 GMT -5
I guess 7 years is "almost 10 years" liane - This is total speculation and nonsense. Seems like a thread lock is in order? |
|
|
|
Post by orlon on Nov 4, 2015 16:12:45 GMT -5
I wonder what the probability of MNKD surviving as a publicly traded company, given the its long time backer RBC now ranks the company as underperform with a price tar get of $1.00 down from outperform at $9.00, some of its retail investors sabotaging the company by lending their shares to shorts, a partner that apparently is doing little other than set up trials with other drugs and has a secret plan that know else knows about, poor sales data, and a management team that appears to be acting not in the best interest of the stockholders, or their own product for that matter..regardless of what Matt said during the last CC. I looked back and saw that I bought a thousand shares almost ten years ago for just over $2.50/shr...not a lot of progress. My guess is the company gets delisted and put on the pinks by the end of the first quarter of. 2016...just my opinion based on past history. I am curious how many times in the past MNKD has been delisted that you can infer a future for it based on induction? As for the timing of it, I would make my own guess based on the fact that a company has to be out of compliance with listing requirements for NASDAQ for 30 days and then has 90 days to remedy the situation, and then an lengthy appeals process before being delisted that there is a 0% chance that your guess is correct. As for your other claims - in the short term, none of those things you listed would change the financial outlook of MNKD in the next 90 days. In the long term, I don't know of a single company that has survived as a publicly traded company longer than 44 years on the NASDAQ (February of 1971 was when the NASDAQ was founded), so I would say the probability of long term survival of MNKD is 0% Of course, no one I know gets out of life alive either, but maybe someone will prove me wrong. My statement and opinion is nothing to get you knickers in a twist about...but thanks for the valuable insight. |
|
|
|
Post by thekindaguyiyam on Nov 4, 2015 16:24:34 GMT -5
Seven years ago it was $2.57. only 3 years off orlon. makes me wonder how far into the paradigm shift Mannkind will be 3 years from now? To celebrate your attempt to make me afraid; I'll buy some more tomorrow. Thanks for the contrarian confirmation! Good luck to you, being a Shorty engaging educated longs, you are going to need it. |
|
|
|
Post by pengiep on Nov 4, 2015 16:25:38 GMT -5
Adnan is "Adnan Butt" the most appropriately named and worst biotech stock analyst still drawing a paycheck.
|
|
